Clinical Trial Update: Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating second-line chemotherapy combined with endostatin for recurrent/metastatic head and neck epithelial tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Neoplasms

Drugs mentioned

• Endostatin (endostatin)
• second-line chemotherapy

Snippet

Sponsor: Sun Yan | Conditions: Head and Neck Neoplasms | Phase 2 | Status: UNKNOWN